MCID: BPL002
MIFTS: 50

Bipolar I Disorder

Categories: Rare diseases, Mental diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 72 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 34 296.50
SNOMED-CT 64 49468007

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to tardive dyskinesia and schizoaffective disorder. An important gene associated with Bipolar I Disorder is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are G-Beta Gamma Signaling and Neuroscience. The drugs Aripiprazole and Carbamazepine have been mentioned in the context of this disorder. Affiliated tissues include amygdala, brain and cortex, and related phenotypes are behavior/neurological and muscle

Wikipedia : 72 Bipolar I disorder (BD-I; pronounced \"type one bipolar disorder\") is a bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 30.0 COMT HTR2A
2 schizoaffective disorder 30.0 BDNF COMT DTNBP1 HTR2A SLC6A4
3 substance abuse 30.0 BDNF COMT SLC6A4
4 autism spectrum disorder 29.6 BDNF COMT HTR2A SLC6A4
5 anxiety 29.0 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
6 autism 28.8 ANK3 BDNF COMT HTR1A HTR2A SLC6A4
7 personality disorder 28.8 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
8 bipolar disorder 28.8 ANK3 BDNF COMT DAO DRD1 DTNBP1
9 borderline personality disorder 28.6 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
10 major depressive disorder 28.5 ANK3 BDNF COMT HTR1A HTR2A HTR2C
11 attention deficit-hyperactivity disorder 28.4 BDNF COMT DRD1 HTR1A HTR2A HTR2C
12 obsessive-compulsive disorder 28.3 BDNF COMT DRD1 HTR1A HTR2A HTR2C
13 panic disorder 28.3 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
14 mood disorder 28.3 BDNF COMT HTR1A HTR2A HTR2C PER3
15 alcohol dependence 28.0 BDNF COMT DRD1 HTR1A HTR2A HTR2C
16 schizophrenia 28.0 BDNF COMT DAO DRD1 DTNBP1 HTR1A
17 psychotic disorder 26.7 BDNF COMT DAO DRD1 DTNBP1 HTR1A
18 alzheimer disease 5 10.4 HTR2A SLC6A4
19 oppositional defiant disorder 10.3 COMT SLC6A4
20 schizophreniform disorder 10.3 COMT NRG1
21 alcoholic psychosis 10.3 HTR2A SLC6A4
22 childhood-onset schizophrenia 10.3 COMT NRG1
23 dysthymic disorder 10.3 HTR2A SLC6A4
24 schizophrenia 5 10.3 HTR1A HTR2A
25 schizoid personality disorder 10.3 HTR1A HTR2A
26 specific developmental disorder 10.3 BDNF COMT SLC6A4
27 hypoactive sexual desire disorder 10.3 HTR1A HTR2A
28 bruxism 10.3 HTR2A SLC6A4
29 substance-induced psychosis 10.3 HTR1A HTR2A
30 aging 10.3
31 kleptomania 10.3 HTR1A SLC6A4
32 cannabis dependence 10.3 COMT NRG1
33 phobic disorder 10.2 COMT HTR1A SLC6A4
34 brunner syndrome 10.2 COMT HTR1A SLC6A4
35 alexithymia 10.2 COMT HTR1A SLC6A4
36 chronic fatigue syndrome 10.2 COMT HTR1A SLC6A4
37 pathological gambling 10.2 DRD1 HTR2A SLC6A4
38 central nervous system disease 10.2 BDNF HTR2A SLC6A4
39 intermittent explosive disorder 10.2 HTR1A SLC6A4
40 serotonin syndrome 10.1 HTR1A HTR2A SLC6A4
41 drug-induced mental disorder 10.1 HTR1A HTR2A
42 paranoid schizophrenia 10.1 BDNF COMT HTR2A SLC6A4
43 bulimia nervosa 1 10.1 BDNF COMT HTR2A SLC6A4
44 post-traumatic stress disorder 10.1 BDNF COMT HTR2A SLC6A4
45 bulimia nervosa 2 10.1 BDNF COMT HTR2A SLC6A4
46 postpartum depression 10.1 BDNF COMT HTR1A SLC6A4
47 drug psychosis 10.1 HTR1A HTR2A
48 agoraphobia 10.0 HTR1A SLC6A4
49 narcolepsy 10.0 COMT DRD1 HTR2A
50 traumatic brain injury 10.0 BDNF COMT

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 BDNF COMT DAO DRD1 DTNBP1 EGR3
2 muscle MP:0005369 9.43 HTR2C SLC6A4 DRD1 DTNBP1 EGR3 HTR2A
3 nervous system MP:0003631 9.4 ANK3 BDNF COMT DAO DRD1 DTNBP1

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
2
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 1 298-46-4 2554
3
Coal tar Approved Phase 4 8007-45-2
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
5
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
6
Oxcarbazepine Approved Phase 4 28721-07-5 34312
7
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
8
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
9
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
10
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
11
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
12
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
13
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
14
Infliximab Approved Phase 4 170277-31-3
15 tannic acid Approved, Nutraceutical Phase 4
16
Choline Approved, Nutraceutical Phase 4 62-49-7 305
17 Antidepressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
18 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Lithium carbonate Phase 4,Phase 3,Phase 2,Early Phase 1 554-13-2
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Quetiapine Fumarate Phase 4,Phase 3,Phase 2 111974-72-2
25 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
28 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
29 Antiemetics Phase 4,Phase 3
30 Autonomic Agents Phase 4,Phase 3
31 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
32 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
33 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Gastrointestinal Agents Phase 4,Phase 3
37 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
40 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
42 Serotonin Uptake Inhibitors Phase 4,Phase 3
43 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
44 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
47 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Obesity Agents Phase 4,Phase 3
49 Appetite Depressants Phase 4
50 Anesthetics Phase 4,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 201)

# Name Status NCT ID Phase Drugs
1 Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
2 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
3 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
4 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder Completed NCT00034580 Phase 4 olanzapine;risperidone
5 A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
6 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
7 The Young Adult and Pediatric Bipolar Study Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
8 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
9 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
10 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
11 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
12 Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
13 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
14 Efficacy of Combined Treatment for Young Bipolar I Disorder Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
15 Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania Completed NCT00190892 Phase 4 olanzapine;carbamazepine
16 Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
17 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
18 A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
19 Sequential Multiple Assignment Treatment for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium/Lithium Carbonate;Divalproex;Lamotrigine;Quetiapine
20 Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations Completed NCT01181960 Phase 4 Risperidone long acting injectable - New Starts;Risperidone long acting injectable - Continuous Users;Paliperidone Palmitate -New and Continuous Users;Other Antipsychotics - New Starts
21 ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
22 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
23 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4 infliximab (remicade);Placebo
24 DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
25 Efficacy of rTMS in Bipolar I Depression Recruiting NCT02749006 Phase 4
26 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Active, not recruiting NCT00608075 Phase 4 lithium;Lithium
27 Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Terminated NCT00139074 Phase 4 Quetiapine fumarate;sodium valproate
28 Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment
29 Safety and Efficacy Study of Lithium in Bipolar Disorder Unknown status NCT00422331 Phase 3 Lithium Carbonate Capsule
30 Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder Unknown status NCT00221429 Phase 3 lithium sodium divalproex
31 Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder Completed NCT01059539 Phase 3 cariprazine
32 A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents Completed NCT00195780 Phase 3 Divalproex Sodium (Depakote ER)
33 Safety and Efficacy of Cariprazine for Bipolar I Disorder Completed NCT01058668 Phase 3 Cariprazine;Placebo
34 Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder Completed NCT00107731 Phase 3 quetiapine fumarate;lithium;divalproex
35 Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder Completed NCT00227305 Phase 3 quetiapine fumarate
36 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who H Completed NCT01575561 Phase 3 Lurasidone
37 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00238485 Phase 3 Licarbazepine
38 Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed Completed NCT00618748 Phase 3 Olanzapine
39 Lurasidone and Cognition in Bipolar I Disorder Completed NCT02147379 Phase 3 Lurasidone
40 A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder Completed NCT00490971 Phase 3 Olanzapine;Paliperidone ER;Placebo
41 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01305408 Phase 3 Armodafinil;Placebo
42 Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01121536 Phase 3 Armodafinil
43 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072630 Phase 3 Armodafinil;Placebo
44 A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072929 Phase 3 Armodafinil;Placebo
45 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Completed NCT00129220 Phase 3 olanzapine;haloperidol;placebo
46 Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) Completed NCT00265330 Phase 3 Ziprasidone oral capsules
47 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. Completed NCT00228059 Phase 3 Licarbazepine
48 Aripiprazole in Children and Adolescents With Bipolar I Disorder Completed NCT00110461 Phase 3 Aripiprazole;Aripiprazole;placebo
49 A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode Completed NCT00094432 Phase 3 Aripiprazole;Placebo
50 An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients Completed NCT00550407 Phase 3 lamotrigine;Placebo

Search NIH Clinical Center for Bipolar I Disorder

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

38
Amygdala, Brain, Cortex, Bone, Cingulate Cortex, Prefrontal Cortex, Testes

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 657)
# Title Authors Year
1
Cognitive functioning in first episode bipolar I disorder patients with and without history of psychosis. ( 29055258 )
2018
2
Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 29316520 )
2018
3
Perception of inpatients following remission of a manic episode in bipolar I disorder on a group-based Psychoeducation program: a qualitative study. ( 29378562 )
2018
4
Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. ( 29391801 )
2018
5
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. ( 29174738 )
2018
6
Assessment of cognitive functions in bipolar I disorder: A 1-year naturalistic follow-up study. ( 29314557 )
2018
7
Glycogen synthase kinase-3I^ activity and cognitive functioning in patients with bipolar I disorder. ( 29433844 )
2018
8
Predictors and outcomes of somatization in bipolar I disorder: A latent class mixture modeling approach. ( 29174742 )
2018
9
Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults. ( 29341822 )
2018
10
Mixed Features in Bipolar I Disorder and the Effect of Lithium on Suicide. ( 29301424 )
2018
11
An overview of pharmacotherapy for bipolar I disorder. ( 29361880 )
2018
12
No neuronal autoantibodies detected in plasma of patients with a bipolar I disorder. ( 29136601 )
2018
13
Neurocognitive functioning, clinical course and functional outcome in first-treatment bipolar I disorder patients with and without clinical relapse: A 1-year follow-up study. ( 29121444 )
2017
14
The CACNA1C risk allele rs1006737 is associated with age-related prefrontal cortical thinning in bipolar I disorder. ( 28398341 )
2017
15
Dysregulation of objectively assessed 24-hour motor activity patterns as a potential marker for bipolar I disorder: results of a community-based family study. ( 28892068 )
2017
16
Bipolar I disorder in remission vs. schizophrenia in remission: Is there a difference in burden? ( 27816846 )
2017
17
Comparison of metabolic syndrome prevalence in patients with schizophrenia and bipolar I disorder. ( 28927969 )
2017
18
Autistic and schizotypal traits and global functioning in bipolar I disorder. ( 27736738 )
2017
19
Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. ( 29170943 )
2017
20
Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis. ( 29119668 )
2017
21
Biological dysrhythm in remitted bipolar I disorder. ( 28559123 )
2017
22
Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. ( 28689688 )
2017
23
Personality disorder symptom severity predicts onset of mood episodes and conversion to bipolar I disorder in individuals with bipolar spectrum disorder. ( 28368159 )
2017
24
Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. ( 28939419 )
2017
25
Association between the zinc finger protein 804A (ZNF804A) gene and the risk of schizophrenia and bipolar I disorder across diagnostic boundaries. ( 28544350 )
2017
26
The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. ( 28843918 )
2017
27
Epidemiology of DSM-5 bipolar I disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III. ( 27814503 )
2017
28
Recommencing lithium in Older Adults with Bipolar I Disorder. ( 29087206 )
2017
29
Neurocognition in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 28709024 )
2017
30
Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. ( 28662460 )
2017
31
Preventive Effects of Lamotrigine in Bipolar II Versus Bipolar I Disorder. ( 28817765 )
2017
32
Olfactory Neuroepithelial Neural Progenitor Cells from Subjects with Bipolar I Disorder. ( 28469524 )
2017
33
Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. ( 29270013 )
2017
34
Clinical pharmacokinetic interactions between lamotrigine and hormonal contraceptives in bipolar I disorder. ( 28191687 )
2017
35
Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. ( 28946761 )
2017
36
Disrupted cortico-limbic connectivity during reward processing in remitted bipolar I disorder. ( 29024194 )
2017
37
Increased cooperative behavior across remitted bipolar I disorder and major depression: Insights utilizing a behavioral economic trust game. ( 27868424 )
2017
38
Solar insolation in springtime influences age of onset of bipolar I disorder. ( 28722128 )
2017
39
Increased hippocampal, thalamus and amygdala volume in long-term lithium-treated bipolar I disorder patients compared with unmedicated patients and healthy subjects. ( 28239952 )
2017
40
Facial emotion labeling in unaffected offspring of adults with bipolar I disorder. ( 27792963 )
2017
41
Joint analysis of cognitive and circadian variation in Schizophrenia and Bipolar I Disorder. ( 29158147 )
2017
42
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder. ( 27755982 )
2017
43
Plasma interleukin-6 in remitted early bipolar I disorder and subjects at high-risk for bipolar disorder. ( 28365164 )
2017
44
Effectiveness of the Dader Method for Pharmaceutical Care on Patients with Bipolar I Disorder: Results from the EMDADER-TAB Study. ( 28025928 )
2017
45
Neurocognitive function in clinically stable individuals with long-term bipolar I disorder: Comparisons with schizophrenia patients and controls. ( 28433073 )
2017
46
Cortisol levels in fingernails, neurocognitive performance and clinical variables in euthymic bipolar I disorder. ( 28345388 )
2017
47
Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. ( 29163985 )
2017
48
Non-Compliance and Related Factors in Patients With Bipolar I Disorder: A Six Month Follow-Up Study. ( 27803718 )
2016
49
Cabergoline can induce mania with psychotic features in bipolar I disorder: a case report. ( 27520906 )
2016
50
Relationships Between Altered Functional Magnetic Resonance Imaging Activation and Cortical Thickness in Patients With Euthymic Bipolar I Disorder. ( 27990494 )
2016

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.96 ANK3 COMT DRD1 DTNBP1 GRID1 HTR1A
2 integral component of plasma membrane GO:0005887 9.8 DRD1 HTR1A HTR2A HTR2C NRG1 SLC6A4
3 dendrite GO:0030425 9.46 ANK3 COMT HTR2A NRG1
4 postsynaptic membrane GO:0045211 9.26 ANK3 COMT DTNBP1 GRID1
5 axon GO:0030424 9.02 ANK3 COMT DTNBP1 HTR2A NRG1

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 ANK3 DRD1 DTNBP1 NRG1 SLC6A4
2 response to drug GO:0042493 9.72 COMT DRD1 HTR2A HTR2C SLC6A4
3 locomotory behavior GO:0007626 9.71 DRD1 HTR2C NRG1
4 circadian rhythm GO:0007623 9.7 EGR3 PER3 SLC6A4
5 memory GO:0007613 9.65 DRD1 HTR2A SLC6A4
6 synapse assembly GO:0007416 9.63 BDNF DRD1 NRG1
7 neuronal action potential GO:0019228 9.61 ANK3 DRD1
8 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway GO:0051482 9.6 DRD1 HTR2C
9 regulation of dopamine secretion GO:0014059 9.59 DTNBP1 HTR2A
10 behavioral response to cocaine GO:0048148 9.58 DRD1 HTR2A
11 temperature homeostasis GO:0001659 9.58 DRD1 HTR2A
12 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.57 HTR1A HTR2A
13 vasoconstriction GO:0042310 9.56 HTR1A SLC6A4
14 dopamine metabolic process GO:0042417 9.55 COMT DRD1
15 regulation of dopamine metabolic process GO:0042053 9.51 DRD1 HTR1A
16 regulation of behavior GO:0050795 9.49 HTR1A HTR2A
17 regulation of hormone secretion GO:0046883 9.43 HTR1A HTR2A
18 behavioral fear response GO:0001662 9.43 DRD1 HTR1A HTR2C
19 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.37 HTR2A HTR2C
20 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.16 HTR2A HTR2C
21 behavior GO:0007610 9.13 HTR1A HTR2A HTR2C
22 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR2C

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.62 DRD1 HTR1A HTR2A HTR2C
2 neurotransmitter receptor activity GO:0030594 9.33 HTR1A HTR2A HTR2C
3 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2A HTR2C
4 G-protein coupled serotonin receptor activity GO:0004993 9.13 HTR1A HTR2A HTR2C
5 serotonin binding GO:0051378 8.8 HTR1A HTR2A HTR2C

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....